Mayo Clinic Doctor Says Mark Cuban’s Cost Plus Drugs is Bringing “Access” to U.S. Healthcare
Mark Cuban’s Cost Plus Drugs is making waves in the pharmacy market, gaining more than 1.2 million customers and selling over 1000 generic low-cost drugs at a fraction of the prescription price that Big Pharma puts on the marketplace. The big question now is whether the supply chain can fundamentally shift toward Cuban’s low-cost…
This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.
Free workspace
Turn your Healthcare expertise into content.
Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.
Mark Cuban’s Cost Plus Drugs is making waves in the pharmacy market, gaining more than 1.2 million customers and selling over 1000 generic low-cost drugs at a fraction of the prescription price that Big Pharma puts on the marketplace. The big question now is whether the supply chain can fundamentally shift toward Cuban’s low-cost model as brand-name drugs resist the shift. Assistant Professor of Epidemiology for the Mayo Clinic College of Medicine at Mayo Clinic, Dr. Jose Medina-Inojosa, breaks down the ripple effects from the Cost Plus Drugs approach to drug product logistics.
Dr. Medina-Inojosa’s Thoughts
“Just to give you a little of context, as we all know, we are probably working in the best healthcare system of the world, but one of the major challenges that we have is access, and specifically prescription access is becoming a major problem in the United States. About 18 million people, about 7% of the whole United States, have a lot of trouble accessing medications and this company is probably gonna help some of the problems. They’re based in Dallas, they’re expanding access, they’re negotiating new deals with drug companies, getting access to generic medications that are about 85% cheaper. Talking about, to give you some example for some leukemia medications, it could take a drug from $2,500 to $14 at Mark Cuban’s Cost Plus Drugs, which is extremely exciting.
They’re also working with manufacturing their ordinary prescription medications in Dallas, and I think down the line they’re promising to continue to expand their deals and their reach over the next six or 12 months. So it’s not the major solution to fix all the problems, but I think it’s a really good step in the right direction. And I’m looking forward to see how it will help shape the face of healthcare and how it will help deliver access.”
Your experts belong here
Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.
Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.
About the author
Dr. José Medina-Inojosa is a cardiovascular disease fellow at Emory University School of Medicine. His earlier work at Mayo Clinic included research on central obesity and cardiovascular risk. In his MarketScale conversations, he returns to practical questions: can a patient reach the clinician, obtain the prescription and understand why a recommendation matters? He co-hosted Health Matters with Alisa Johnsrud in 2021, bringing clinicians into conversations about prevention, health equity and public-health information. His later contributions explore virtual assessments, remote specialist collaboration and the transition to value-based care. In a discussion of body-volume assessment, he put the hoped-for benefit of technology in personal terms: less workload for practitioners and more useful face-to-face interaction with patients.
